의약품 품질 관리 및 컴플라이언스 시장 : 시장 규모, 점유율, 성장, 업계 분석, 지역별 동향 및 예측(2026-2034년)

Growth Factors of pharma quality control and compliance Market

The global pharma quality control and compliance market was valued at USD 10.79 billion in 2025 and is projected to grow from USD 11.58 billion in 2026 to USD 22.82 billion by 2034, registering a CAGR of 8.85% during the forecast period. North America dominated the market with a 38.27% share in 2025, supported by its strong pharmaceutical manufacturing base, advanced quality management infrastructure, and stringent regulatory framework.

Pharma quality control and compliance solutions are critical for ensuring drug safety, efficacy, and regulatory adherence throughout the pharmaceutical manufacturing process. These systems support raw material testing, microbiological analysis, batch-release procedures, stability studies, GMP compliance, validation activities, and documentation management. Increasing manufacturing complexity in biologics, vaccines, cell therapies, and gene therapies is driving substantial investments in advanced quality control technologies and compliance platforms.

Market Size and Forecast

Year Market Value (USD Billion)

2025 10.79

2026 11.58

2034 22.82

The market's expansion is fueled by rising pharmaceutical production, growing regulatory scrutiny, and increasing adoption of digital quality management systems.

Market Trends

Growing Adoption of Automated Compliance Solutions

One of the most prominent trends in the pharma quality control and compliance market is the shift from traditional paper-based quality systems toward automated digital platforms. Pharmaceutical companies are increasingly implementing electronic Quality Management Systems (eQMS), Laboratory Information Management Systems (LIMS), AI-enabled compliance tools, and digital batch-release platforms.

These technologies enhance traceability, reduce documentation errors, improve audit readiness, and strengthen data integrity across manufacturing operations. In January 2025, Honeywell launched the TrackWise Life Sciences Platform to help life sciences companies integrate manufacturing and quality management through advanced automation and digital transformation.

Market Drivers

Increasing Drug Development Activities

The rapid growth of pharmaceutical and biotechnology pipelines is a major factor driving market demand. New drug development programs require extensive quality testing, stability studies, microbiological assessments, validation activities, and regulatory documentation.

As companies expand research and manufacturing activities for biologics, vaccines, and advanced therapies, the need for sophisticated quality control systems continues to rise. In April 2025, Novartis announced plans to invest USD 23 billion in expanding its U.S. manufacturing and R&D infrastructure, highlighting the growing focus on quality-focused production capabilities.

Market Restraints

Stringent Regulatory Requirements

Regulatory compliance remains one of the most challenging aspects of pharmaceutical manufacturing. Companies must continuously invest in validated systems, quality oversight programs, employee training, contamination control measures, and documentation management to satisfy global regulatory agencies.

Failure to comply can result in warning letters, delayed product approvals, remediation expenses, and operational disruptions. Regulatory complexity is particularly challenging for small manufacturers and companies operating across multiple regions.

Market Opportunities

Expansion of Outsourced Quality Control Services

The increasing use of outsourced quality control services presents significant growth opportunities. Pharmaceutical manufacturers are increasingly partnering with specialized testing laboratories and compliance service providers to improve efficiency and reduce operational costs.

Organizations such as Charles River Laboratories and Eurofins Scientific offer GMP-certified testing services that help pharmaceutical companies manage complex analytical requirements while maintaining regulatory compliance.

Market Challenges

Maintaining Consistent Global Quality Standards

Global pharmaceutical supply chains continue to become more complex as companies source APIs, excipients, packaging materials, and manufacturing services from multiple countries. Maintaining uniform quality standards across suppliers and manufacturing sites remains a major challenge.

Variations in supplier quality systems, documentation practices, and testing procedures increase compliance risks and require significant investments in supplier audits, digital quality platforms, and global oversight programs.

Segmentation Analysis

By Offering

The products segment dominated the market in 2025 due to the extensive use of instruments and consumables in pharmaceutical testing and quality assurance operations. Chromatography systems, microbiological testing equipment, filters, reagents, and monitoring instruments remain essential for GMP-compliant manufacturing.

The software segment is projected to witness the fastest growth with increasing adoption of cloud-based quality management and compliance platforms.

By Application

The small molecule drugs segment held the largest market share owing to extensive global manufacturing volumes and continuous demand for analytical testing, stability studies, and batch-release activities. The segment is expected to account for 54.3% of the market in 2026.

By Function

The finished product testing and batch release segment dominated the market in 2025 and is projected to hold 21.3% market share in 2026. Every pharmaceutical batch must undergo comprehensive quality verification before commercial release, making this function critical to overall compliance operations.

By End User

The pharmaceutical and biotechnology companies segment accounted for the largest market share in 2025 and is expected to maintain 71.4% share in 2026. These organizations remain the largest purchasers of QC instruments, software platforms, validation tools, and compliance services.

Regional Analysis

North America

North America led the market with a value of USD 4.13 billion in 2025. The region benefits from advanced pharmaceutical manufacturing facilities, strong regulatory enforcement, and substantial investments in quality assurance technologies.

Europe

Europe is projected to grow at a CAGR of 7.90% during the forecast period. Strong biologics manufacturing capabilities and established GMP standards continue to support regional growth.

Asia Pacific

Asia Pacific is expected to be the fastest-growing region, reaching USD 2.76 billion in 2026. Rapid pharmaceutical manufacturing expansion in China and India is driving increased investment in QC laboratories, contamination control systems, and regulatory compliance solutions.

Latin America and Middle East & Africa

These regions are anticipated to witness moderate growth due to increasing local pharmaceutical production, strengthening regulatory frameworks, and growing focus on reducing reliance on imported medicines.

Competitive Landscape

Leading companies operating in the pharma quality control and compliance market include:

• Thermo Fisher Scientific Inc.
• Agilent Technologies, Inc.
• Waters Corporation
• Veeva Systems
• Honeywell International Inc.
• Sartorius AG
• Charles River Laboratories
• Eurofins Scientific
• LabVantage Solutions Inc.
• LabWare

These companies are focusing on integrated quality ecosystems, automation, cloud-based compliance solutions, and AI-enabled laboratory management platforms to strengthen their market positions.

Recent Industry Developments

• January 2026: Charles River Laboratories announced plans to acquire PathoQuest to strengthen biologics testing and GMP quality control capabilities.
• May 2025: Waters Corporation expanded Empower Software capabilities to support biologics QC analysis.
• March 2025: LabVantage launched version 8.9 of its LIMS platform with AI-driven workflow enhancements.
• March 2025: LabWare expanded its SaaS portfolio with LabWare ASSURE and LabWare QAQC solutions.
• January 2025: Veeva and Zifo collaborated to accelerate quality control modernization through integrated LIMS solutions.

Conclusion

The pharma quality control and compliance market is poised for strong growth through 2034, driven by increasing pharmaceutical production, expanding biologics and advanced therapy pipelines, and stricter regulatory requirements worldwide. The growing adoption of automated compliance systems, cloud-based quality management platforms, and outsourced testing services is transforming the industry. While regulatory complexity and global supply-chain quality challenges remain significant concerns, continued investments in digital quality ecosystems, laboratory automation, and advanced compliance technologies will create substantial opportunities for market participants. As pharmaceutical companies focus on ensuring product safety, data integrity, and regulatory readiness, quality control and compliance solutions will remain a strategic priority across the global healthcare industry.

Segmentation By Offering, Application, Function, End User, and Region

By Offering * Products

• Instruments
• Consumables
• Software
• Services

By Application * Small Molecule Drugs

• Biologics and Biosimilars
• Vaccines
• Cell and Gene Therapies
• Others

By Function * Raw Material Quality Control

• Microbiology and Contamination Control
• Stability and Shelf-life Testing
• In-process Quality Control
• Finished Product Testing and Batch Release
• Regulatory Compliance Management
• Validation & Qualification / Quality Systems Management
• Others

By End User * Pharmaceutical & Biotechnology Companies

• CROs & CDMOs
• Others

By Region * North America (By Offering, Application, Function, End User, and Country)

• U.S.
• Canada
• Europe (By Offering, Application, Function, End User, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Offering, Application, Function, End User, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Offering, Application, Function, End User, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Offering, Application, Function, End User, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Technological Advancements in Pharma Quality Control and Compliance
• 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• 4.3. New Product Launches, By Key Players
• 4.4. Regulatory Scenario, By Key Countries/Regions

5. Global Pharma Quality Control and Compliance Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Offering
  • 5.1.1. Products
    • 5.1.1.1. Instruments
    • 5.1.1.2. Consumables
  • 5.1.2. Software
  • 5.1.3. Services
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Small Molecule Drugs
  • 5.2.2. Biologics and Biosimilars
  • 5.2.3. Vaccines
  • 5.2.4. Cell and Gene Therapies
  • 5.2.5. Others
• 5.3. Market Analysis, Insights and Forecast - By Function
  • 5.3.1. Raw Material Quality Control
  • 5.3.2. Microbiology and Contamination Control
  • 5.3.3. Stability and Shelf-life Testing
  • 5.3.4. In-process Quality Control
  • 5.3.5. Finished Product Testing and Batch Release
  • 5.3.6. Regulatory Compliance Management
  • 5.3.7. Validation & Qualification / Quality Systems Management
  • 5.3.8. Others
• 5.4. Market Analysis, Insights and Forecast - By End User
  • 5.4.1. Pharmaceutical & Biotechnology Companies
  • 5.4.2. CROs / CDMOs
  • 5.4.3. Others
• 5.5. Market Analysis, Insights and Forecast - Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Pharma Quality Control and Compliance Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Offering
  • 6.1.1. Products
    • 6.1.1.1. Instruments
    • 6.1.1.2. Consumables
  • 6.1.2. Software
  • 6.1.3. Services
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Small Molecule Drugs
  • 6.2.2. Biologics and Biosimilars
  • 6.2.3. Vaccines
  • 6.2.4. Cell and Gene Therapies
  • 6.2.5. Others
• 6.3. Market Analysis, Insights and Forecast - By Function
  • 6.3.1. Raw Material Quality Control
  • 6.3.2. Microbiology and Contamination Control
  • 6.3.3. Stability and Shelf-life Testing
  • 6.3.4. In-process Quality Control
  • 6.3.5. Finished Product Testing and Batch Release
  • 6.3.6. Regulatory Compliance Management
  • 6.3.7. Validation & Qualification / Quality Systems Management
  • 6.3.8. Others
• 6.4. Market Analysis, Insights and Forecast - By End User
  • 6.4.1. Pharmaceutical & Biotechnology Companies
  • 6.4.2. CROs / CDMOs
  • 6.4.3. Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Pharma Quality Control and Compliance Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Offering
  • 7.1.1. Products
    • 7.1.1.1. Instruments
    • 7.1.1.2. Consumables
  • 7.1.2. Software
  • 7.1.3. Services
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Small Molecule Drugs
  • 7.2.2. Biologics and Biosimilars
  • 7.2.3. Vaccines
  • 7.2.4. Cell and Gene Therapies
  • 7.2.5. Others
• 7.3. Market Analysis, Insights and Forecast - By Function
  • 7.3.1. Raw Material Quality Control
  • 7.3.2. Microbiology and Contamination Control
  • 7.3.3. Stability and Shelf-life Testing
  • 7.3.4. In-process Quality Control
  • 7.3.5. Finished Product Testing and Batch Release
  • 7.3.6. Regulatory Compliance Management
  • 7.3.7. Validation & Qualification / Quality Systems Management
  • 7.3.8. Others
• 7.4. Market Analysis, Insights and Forecast - By End User
  • 7.4.1. Pharmaceutical & Biotechnology Companies
  • 7.4.2. CROs / CDMOs
  • 7.4.3. Others
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Pharma Quality Control and Compliance Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Offering
  • 8.1.1. Products
    • 8.1.1.1. Instruments
    • 8.1.1.2. Consumables
  • 8.1.2. Software
  • 8.1.3. Services
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Small Molecule Drugs
  • 8.2.2. Biologics and Biosimilars
  • 8.2.3. Vaccines
  • 8.2.4. Cell and Gene Therapies
  • 8.2.5. Others
• 8.3. Market Analysis, Insights and Forecast - By Function
  • 8.3.1. Raw Material Quality Control
  • 8.3.2. Microbiology and Contamination Control
  • 8.3.3. Stability and Shelf-life Testing
  • 8.3.4. In-process Quality Control
  • 8.3.5. Finished Product Testing and Batch Release
  • 8.3.6. Regulatory Compliance Management
  • 8.3.7. Validation & Qualification / Quality Systems Management
  • 8.3.8. Others
• 8.4. Market Analysis, Insights and Forecast - By End User
  • 8.4.1. Pharmaceutical & Biotechnology Companies
  • 8.4.2. CROs / CDMOs
  • 8.4.3. Others
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.5.1. China
  • 8.5.2. Japan
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Pharma Quality Control and Compliance Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Offering
  • 9.1.1. Products
    • 9.1.1.1. Instruments
    • 9.1.1.2. Consumables
  • 9.1.2. Software
  • 9.1.3. Services
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Small Molecule Drugs
  • 9.2.2. Biologics and Biosimilars
  • 9.2.3. Vaccines
  • 9.2.4. Cell and Gene Therapies
  • 9.2.5. Others
• 9.3. Market Analysis, Insights and Forecast - By Function
  • 9.3.1. Raw Material Quality Control
  • 9.3.2. Microbiology and Contamination Control
  • 9.3.3. Stability and Shelf-life Testing
  • 9.3.4. In-process Quality Control
  • 9.3.5. Finished Product Testing and Batch Release
  • 9.3.6. Regulatory Compliance Management
  • 9.3.7. Validation & Qualification / Quality Systems Management
  • 9.3.8. Others
• 9.4. Market Analysis, Insights and Forecast - By End User
  • 9.4.1. Pharmaceutical & Biotechnology Companies
  • 9.4.2. CROs / CDMOs
  • 9.4.3. Others
• 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Pharma Quality Control and Compliance Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Offering
  • 10.1.1. Products
    • 10.1.1.1. Instruments
    • 10.1.1.2. Consumables
  • 10.1.2. Software
  • 10.1.3. Services
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Small Molecule Drugs
  • 10.2.2. Biologics and Biosimilars
  • 10.2.3. Vaccines
  • 10.2.4. Cell and Gene Therapies
  • 10.2.5. Others
• 10.3. Market Analysis, Insights and Forecast - By Function
  • 10.3.1. Raw Material Quality Control
  • 10.3.2. Microbiology and Contamination Control
  • 10.3.3. Stability and Shelf-life Testing
  • 10.3.4. In-process Quality Control
  • 10.3.5. Finished Product Testing and Batch Release
  • 10.3.6. Regulatory Compliance Management
  • 10.3.7. Validation & Qualification / Quality Systems Management
  • 10.3.8. Others
• 10.4. Market Analysis, Insights and Forecast - By End User
  • 10.4.1. Pharmaceutical & Biotechnology Companies
  • 10.4.2. CROs / CDMOs
  • 10.4.3. Others
• 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of the Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Thermo Fisher Scientific Inc.
  • 11.2.2. Agilent Technologies, Inc.
  • 11.2.3. Waters Corporation
  • 11.2.4. Veeva Systems
  • 11.2.5. Honeywell International Inc.
  • 11.2.6. Sartorius AG
  • 11.2.7. Charles River Laboratories
  • 11.2.8. Eurofins Scientific
  • 11.2.9. LabVantage Solutions Inc.
  • 11.2.10. LabWare